Dr Michael Thomas Werner, MD, PHD | |
2000 Marcus Ave, New Hyde Park, NY 11042-1069 | |
(516) 321-6000 | |
Not Available |
Full Name | Dr Michael Thomas Werner |
---|---|
Gender | Male |
Speciality | Student In An Organized Health Care Education/training Program |
Location | 2000 Marcus Ave, New Hyde Park, New York |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1598344236 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Y00000X | Otolaryngology | TBD (New York) | Secondary |
390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Michael Thomas Werner, MD, PHD 2000 Marcus Ave, New Hyde Park, NY 11042-1069 Ph: (516) 321-6000 | Dr Michael Thomas Werner, MD, PHD 2000 Marcus Ave, New Hyde Park, NY 11042-1069 Ph: (516) 321-6000 |
News Archive
As COVID-19 cases surge in the U.S., the nation is waiting for the availability of a safe and effective vaccine.
An Ontario-led international clinical trial with 1,206 men with localized prostate cancer shows that compressing radiation treatments into four weeks from eight delivers similar outcomes.
Plexxikon Inc., a member of Daiichi Sankyo Group, today announced scientific findings from preclinical studies showing that treatment with a novel oral agent, PLX3397, selectively inhibited key cancer-driving Flt3 mutations that occur in 20-30 percent of acute myeloid leukemia (AML) patients.
Post-operative radiotherapy (PORT) used in patients with non-small-cell lung cancer (NSCLC) following complete resection and after (neo) adjuvant chemotherapy shows no statistically significant difference in 3-year disease-free survival (DFS), according to data presented at ESMO 2020.
› Verified 7 days ago